SCHEMBL10116459

SCHEMBL10116459

CC(C)(C)C(=O)Oc1cc(F)c(C(O)CN)cc1OC(=O)C(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 3/20 0.46
CYP3A4 P08684 2/20 0.46
ADRB2 P07550 2/20 0.46
ADRA2C P18825 2/20 0.46
ADRA2A P08913 2/20 0.46
HSD17B10 Q99714 1/20 0.46
ADRA2B P18089 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
HIF1A Q16665 1/20 0.46
KDM4E B2RXH2 1/20 0.45
MAPT P10636 1/20 0.45
APEX1 P27695 1/20 0.45
RAD52 P43351 1/20 0.45
RECQL P46063 1/20 0.45
BLM P54132 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
KDM4C Q9H3R0 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10116451 0.90 ADRB2 (0.54) ADRA1ACYP3A4ADRB2ADRA2CADRA2A
SCHEMBL12287039 0.90 ADRB2 (0.54) ADRA1ACYP3A4ADRB2ADRA2CADRA2A
SCHEMBL10116452 0.88 ALDH1A1 (0.49) ADRA1ACYP3A4ADRB2ADRA2CADRA2A
SCHEMBL16687896 0.79 ALDH1A1 (0.44) ADRA1ACYP3A4ADRB2ADRA2CADRA2A
SCHEMBL10116454 0.79 CYP3A4 (0.43) ADRA1ACYP3A4ADRB2ADRA2CADRA2A
SCHEMBL23339689 0.77 LMNA (0.71) ADRA1ACYP3A4ADRB2ADRA2CADRA2A
SCHEMBL11526487 0.77 LMNA (0.71) ADRA1ACYP3A4ADRB2ADRA2CADRA2A
SCHEMBL8904463 0.76 ADRA1A (0.56) ADRA1ACYP3A4ADRB2ADRA2CADRA2A
SCHEMBL23720612 0.76 HTR2A (0.47) CYP3A4ADRB2ALDH1A1LMNAHIF1A
Hydrochloric Acid SCHEMBL8905797 0.74 BLM (0.58) ADRA1ACYP3A4ADRB2ADRA2CADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9023788-B2 Methods compounds and pharmaceutical compositions for treating anxiety and mood disorders NEW YORK UNIVERSITY (US) 2015-05-05 US disclosed
US-9023788-B2 Methods compounds and pharmaceutical compositions for treating anxiety and mood disorders NEW YORK UNIVERSITY (US) 2015-05-05 US disclosed
WO-2012142388-A2 METHODS, COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING ANXIETY AND MOOD DISORDERS NEW YORK UNIVERSITY (US) 2012-10-18 WO disclosed
US-20120010125-A1 Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders STONE ERIC A (US) 2012-01-12 US disclosed
US-20120010125-A1 Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders STONE ERIC A (US) 2012-01-12 US disclosed
WO-2011133212-A1 METHODS, COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING ANXIETY AND MOOD DISORDERS NEW YORK UNIVERSITY (US) 2011-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010125-A1 Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders HTR1B, HTR1A, HTR2B ADRA1A 20/4885CYP3A4 906/4885ADRB2 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.